Overview
- The selection includes Trulicity, Botox for Medicare-covered uses, Biktarvy, and multiple cancer and autoimmune therapies.
- Manufacturers must decide by Feb. 28, 2026 whether to participate, with negotiations running through 2026 and new prices taking effect Jan. 1, 2028.
- CMS also chose to renegotiate Tradjenta, a Type 2 diabetes drug previously slated for 2027 price reductions.
- Physician-administered Part B medicines are included for the first time, expanding the program’s scope and posing added implementation challenges.
- Reaction split along familiar lines, with AARP welcoming potential savings and PhRMA warning the IRA’s approach could deter future drug development.